A Key Agonist-induced Conformational Change in the Cannabinoid Receptor CB1 is Blocked by the Allosteric Ligand Org 27569

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2012 Aug 1

PMID 22846992

Citations 30

Authors

Jonathan F Fay

David L Farrens

Affiliations

Soon will be listed here.

Abstract

Allosteric ligands that modulate how G protein-coupled receptors respond to traditional orthosteric drugs are an exciting and rapidly expanding field of pharmacology. An allosteric ligand for the cannabinoid receptor CB1, Org 27569, exhibits an intriguing effect; it increases agonist binding, yet blocks agonist-induced CB1 signaling. Here we explored the mechanism behind this behavior, using a site-directed fluorescence labeling approach. Our results show that Org 27569 blocks conformational changes in CB1 that accompany G protein binding and/or activation, and thus inhibit formation of a fully active CB1 structure. The underlying mechanism behind this behavior is that simultaneous binding of Org 27569 produces a unique agonist-bound conformation, one that may resemble an intermediate structure formed on the pathway to full receptor activation.

Citing Articles

Insight into the mechanism of action of ORG27569 at the cannabinoid type one receptor utilising a unified mathematical model.

Green H, Yang L, Zhu X, Finlay D, Duffull S, Glass M Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):5105-5118.

PMID: 38227196 PMC: 11166842. DOI: 10.1007/s00210-023-02923-6.

A rapid, tag-free way to purify functional GPCRs.

Shumate A, Farrens D J Biol Chem. 2023; 300(1):105558.

PMID: 38097184 PMC: 10820827. DOI: 10.1016/j.jbc.2023.105558.

The NPXXY Motif Regulates β-Arrestin Recruitment by the CB1 Cannabinoid Receptor.

Leo L, Al-Zoubi R, Hurst D, Stephan A, Zhao P, Tilley D Cannabis Cannabinoid Res. 2022; 8(5):731-748.

PMID: 35792570 PMC: 10589503. DOI: 10.1089/can.2021.0223.

Discovery and Characterization of the First Nonpeptide Antagonists for the Relaxin-3/RXFP3 System.

Gay E, Guan D, Van Voorhies K, Vasukuttan V, Mathews K, Besheer J J Med Chem. 2022; 65(11):7959-7974.

PMID: 35594150 PMC: 9255433. DOI: 10.1021/acs.jmedchem.2c00508.

Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling.

Laprairie R, Mohamed K, Zagzoog A, Kelly M, Stevenson L, Pertwee R Front Mol Neurosci. 2019; 12:257.

PMID: 31680861 PMC: 6813218. DOI: 10.3389/fnmol.2019.00257.

References

Xu F, Wu H, Katritch V, Han G, Jacobson K, Gao Z . Structure of an agonist-bound human A2A adenosine receptor. Science. 2011; 332(6027):322-7. PMC: 3086811. DOI: 10.1126/science.1202793. View

De Lean A, Stadel J, Lefkowitz R . A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor. J Biol Chem. 1980; 255(15):7108-17. View

Devane W, Dysarz 3rd F, Johnson M, Melvin L, Howlett A . Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988; 34(5):605-13. View

Kimura T, Cheng K, Rice K, Gawrisch K . Location, structure, and dynamics of the synthetic cannabinoid ligand CP-55,940 in lipid bilayers. Biophys J. 2009; 96(12):4916-24. PMC: 2712040. DOI: 10.1016/j.bpj.2009.03.033. View

Salom D, Lodowski D, Stenkamp R, Le Trong I, Golczak M, Jastrzebska B . Crystal structure of a photoactivated deprotonated intermediate of rhodopsin. Proc Natl Acad Sci U S A. 2006; 103(44):16123-8. PMC: 1637547. DOI: 10.1073/pnas.0608022103. View

Piomelli D . The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003; 4(11):873-84. DOI: 10.1038/nrn1247. View

Yao X, Ruiz G, Whorton M, Rasmussen S, DeVree B, Deupi X . The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci U S A. 2009; 106(23):9501-6. PMC: 2685739. DOI: 10.1073/pnas.0811437106. View

Fay J, Dunham T, Farrens D . Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry. 2005; 44(24):8757-69. DOI: 10.1021/bi0472651. View

Lebon G, Warne T, Edwards P, Bennett K, Langmead C, Leslie A . Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature. 2011; 474(7352):521-5. PMC: 3146096. DOI: 10.1038/nature10136. View

10.

Farrens D . What site-directed labeling studies tell us about the mechanism of rhodopsin activation and G-protein binding. Photochem Photobiol Sci. 2010; 9(11):1466-74. PMC: 3901699. DOI: 10.1039/c0pp00283f. View

11.

Gether U, Lin S, Kobilka B . Fluorescent labeling of purified beta 2 adrenergic receptor. Evidence for ligand-specific conformational changes. J Biol Chem. 1995; 270(47):28268-75. DOI: 10.1074/jbc.270.47.28268. View

12.

Ehlert F . Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol. 1988; 33(2):187-94. View

13.

Farrens D, Dunham T, Fay J, Dews I, Caldwell J, Nauert B . Design, expression, and characterization of a synthetic human cannabinoid receptor and cannabinoid receptor/ G-protein fusion protein. J Pept Res. 2002; 60(6):336-47. DOI: 10.1034/j.1399-3011.2002.21066.x. View

14.

Ghanouni P, Steenhuis J, Farrens D, Kobilka B . Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A. 2001; 98(11):5997-6002. PMC: 33412. DOI: 10.1073/pnas.101126198. View

15.

Price M, Baillie G, Thomas A, Stevenson L, Easson M, Goodwin R . Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005; 68(5):1484-95. DOI: 10.1124/mol.105.016162. View

16.

Rosenbaum D, Zhang C, Lyons J, Holl R, Aragao D, Arlow D . Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature. 2011; 469(7329):236-40. PMC: 3074335. DOI: 10.1038/nature09665. View

17.

Keov P, Sexton P, Christopoulos A . Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. Neuropharmacology. 2010; 60(1):24-35. DOI: 10.1016/j.neuropharm.2010.07.010. View

18.

Janz J, Farrens D . Rhodopsin activation exposes a key hydrophobic binding site for the transducin alpha-subunit C terminus. J Biol Chem. 2004; 279(28):29767-73. DOI: 10.1074/jbc.M402567200. View

19.

Ghanouni P, Gryczynski Z, Steenhuis J, Lee T, Farrens D, Lakowicz J . Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem. 2001; 276(27):24433-6. DOI: 10.1074/jbc.C100162200. View

20.

Mansoor S, Palczewski K, Farrens D . Rhodopsin self-associates in asolectin liposomes. Proc Natl Acad Sci U S A. 2006; 103(9):3060-5. PMC: 1413906. DOI: 10.1073/pnas.0511010103. View